United States. Congress. House. Committee on Commerce. Subcommittee on Oversight and Investigations.

• A consumer's perspective on medical devices
• Adequacy of access to investigative drugs for seriously ill patients
• Allegations of FDA abuses of authority
• Assessing the Department of Energy's management of the national laboratory system
• Blood safety and availability
• Cancer patient access to unapproved treatments
• Circumstances surrounding the FCC's planned relocation to the Portals
• Clean Air Act amendments
• Competition in the cellular telephone service industry
• Consumer access to home testing services and devices
• Continued management concerns at the NIH
• Date rape drugs